ATG4B and hepatocellular carcinoma: Targeted inhibition of ATG4B can block ATG4B-mediated autophagic degradation of TBK1 (a crucial kinase for antiviral immunity), enhancing antiviral immune responses and CD8+ T cell infiltration, thereby delaying HCC progression (25, 26).